Phase III FIRST™ (MM-020/IFM 07-01) trial of REVLIMID® (lenalidomide) plus dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for stem cell transplant published in New England Journal of Medicine

(dna Communications) Study met the primary endpoint as a significant progression-free survival benefit was seen for patients treated with continuous REVLIMID plus dexamethasone compared with those treated with a standard of care.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news